Share Price and Basic Stock Data
Last Updated: October 14, 2025, 7:54 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Omaxe Ltd operates in the construction, contracting, and engineering sector, with a current market capitalization of ₹1,505 Cr and a share price of ₹82.1. The company has reported fluctuating revenue trends over the past quarters, with sales standing at ₹121 Cr in June 2022 and peaking at ₹599 Cr in December 2023. However, sales subsequently declined to ₹342 Cr by June 2024. Annual sales figures also highlight variability, with ₹1,614 Cr reported for March 2024, before slightly declining to ₹1,561 Cr for March 2025. This inconsistency raises concerns regarding the company’s ability to maintain stable revenue growth moving forward. Additionally, the company’s operating profit margin (OPM) has remained negative, recording -60% at the latest reporting period, indicating significant challenges in managing costs effectively. Overall, while there are instances of revenue growth, the volatility and recent downturn suggest a need for strategic adjustments to bolster performance.
Profitability and Efficiency Metrics
Omaxe Ltd’s profitability metrics present a bleak picture, with net profits consistently in the negative territory. The company reported a net loss of ₹685 Cr for March 2025, a deterioration from a loss of ₹406 Cr in March 2024. The operating profit has also been negative across several periods, with a reported operating loss of ₹608 Cr for March 2025 and a negative operating profit margin of -39%. This trend is alarming, especially when considering the interest coverage ratio, which stood at -2.72x, indicating that the company is not generating sufficient earnings to cover its interest expenses. The return on equity (ROE) is notably high at 506%, but this figure is misleading due to the negative net profit and equity base. The cash conversion cycle of 73 days suggests some operational efficiency, but it remains a challenge for the company to translate this into sustainable profitability.
Balance Sheet Strength and Financial Ratios
Omaxe Ltd’s balance sheet reveals significant financial strain, particularly regarding its reserves and borrowings. The company reported negative reserves of ₹388 Cr as of March 2025, highlighting a concerning depletion of equity. Borrowings stood at ₹796 Cr, which, in conjunction with negative reserves, raises the debt-to-equity ratio to a troubling level, further exacerbated by a long-term debt-to-equity ratio of -2.43x. The current ratio is relatively low at 0.95, indicating potential liquidity issues, while the quick ratio of 0.16 raises further concerns about the company’s ability to meet short-term obligations. Additionally, the enterprise value (EV) to net operating revenue ratio of 0.92x suggests that the market is not valuing the company’s revenue generation potential favorably. These ratios collectively paint a picture of a company grappling with financial stability and operational effectiveness.
Shareholding Pattern and Investor Confidence
The shareholding structure of Omaxe Ltd illustrates a strong promoter presence at 74.14%, which may provide some degree of stability in decision-making. However, foreign institutional investors (FIIs) have seen a decline in their holdings, dropping from 9.73% in September 2022 to 6.66% in March 2025, indicating waning confidence among international investors. Domestic institutional investors (DIIs) have remained relatively stable at around 2.26%, while the public holding has increased to 16.93% as of March 2025. The number of shareholders has also seen fluctuations, with 48,598 shareholders reported recently. The declining FII interest may raise concerns regarding the company’s attractiveness to institutional investors, potentially impacting future capital raising efforts. This dynamic within the shareholding pattern suggests a mixed sentiment among investors, reflecting both confidence in the promoters and apprehension about the company’s financial health.
Outlook, Risks, and Final Insight
If Omaxe Ltd can stabilize its revenue streams and effectively manage its operational costs, there may be potential for recovery. However, significant risks remain, primarily stemming from its high levels of debt relative to equity and ongoing losses, which could limit operational flexibility and investment in growth initiatives. Additionally, the declining confidence from FIIs suggests that the company must address its financial health to attract external investment. Should the company manage to improve its margins and generate consistent profits, it could potentially regain investor confidence and stabilize its share price. However, without a clear strategic plan addressing these challenges, the risks of further financial deterioration remain high. Therefore, the path forward will require decisive actions to enhance operational efficiency, manage debt levels, and restore profitability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Omaxe Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modern Engineering and Projects Ltd | 64.1 Cr. | 41.5 | 75.1/22.5 | 8.03 | 36.3 | 0.00 % | 20.5 % | 25.9 % | 10.0 |
| Modis Navnirman Ltd | 616 Cr. | 315 | 344/220 | 75.2 | 46.5 | 0.00 % | 12.9 % | 9.88 % | 10.0 |
| Modulex Construction Technologies Ltd | 159 Cr. | 23.0 | 35.7/16.1 | 43.5 | 0.00 % | 2.51 % | 1.54 % | 10.0 | |
| MPDL Ltd | 34.9 Cr. | 47.1 | 92.7/38.0 | 132 | 0.00 % | 2.87 % | 4.16 % | 10.0 | |
| IITL Projects Ltd | 26.4 Cr. | 53.0 | 78.1/34.7 | 2.97 | 0.00 % | 16.6 % | % | 10.0 | |
| Industry Average | 16,200.95 Cr | 245.04 | 44.30 | 127.20 | 0.14% | 16.47% | 23.87% | 21.54 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 119 | 244 | 289 | 213 | 266 | 599 | 536 | 342 | 389 | 289 | 541 | 282 |
| Expenses | 145 | 187 | 346 | 399 | 306 | 333 | 637 | 682 | 493 | 613 | 416 | 647 | 452 |
| Operating Profit | -23 | -68 | -102 | -109 | -93 | -67 | -37 | -146 | -151 | -224 | -127 | -106 | -170 |
| OPM % | -19% | -57% | -42% | -38% | -43% | -25% | -6% | -27% | -44% | -58% | -44% | -20% | -60% |
| Other Income | 3 | 3 | 10 | 9 | 7 | 4 | 3 | 7 | 44 | 9 | 11 | 12 | 16 |
| Interest | 29 | 31 | 27 | 26 | 31 | 29 | 32 | 38 | 42 | 45 | 57 | 51 | 67 |
| Depreciation | 17 | 16 | 16 | 16 | 16 | 10 | 15 | 14 | 7 | 7 | 10 | 12 | 7 |
| Profit before tax | -66 | -112 | -136 | -143 | -132 | -103 | -82 | -191 | -157 | -267 | -183 | -157 | -228 |
| Tax % | -24% | -22% | -20% | -27% | -19% | -18% | -12% | -25% | -6% | -10% | -18% | -5% | -19% |
| Net Profit | -50 | -87 | -109 | -104 | -106 | -84 | -72 | -144 | -147 | -239 | -150 | -149 | -186 |
| EPS in Rs | -2.68 | -4.78 | -5.79 | -5.77 | -5.81 | -4.61 | -3.66 | -7.93 | -8.06 | -13.10 | -8.23 | -8.11 | -10.16 |
Last Updated: August 20, 2025, 6:00 am
Below is a detailed analysis of the quarterly data for Omaxe Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 282.00 Cr.. The value appears to be declining and may need further review. It has decreased from 541.00 Cr. (Mar 2025) to 282.00 Cr., marking a decrease of 259.00 Cr..
- For Expenses, as of Jun 2025, the value is 452.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 647.00 Cr. (Mar 2025) to 452.00 Cr., marking a decrease of 195.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -170.00 Cr.. The value appears to be declining and may need further review. It has decreased from -106.00 Cr. (Mar 2025) to -170.00 Cr., marking a decrease of 64.00 Cr..
- For OPM %, as of Jun 2025, the value is -60.00%. The value appears to be declining and may need further review. It has decreased from -20.00% (Mar 2025) to -60.00%, marking a decrease of 40.00%.
- For Other Income, as of Jun 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 4.00 Cr..
- For Interest, as of Jun 2025, the value is 67.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 51.00 Cr. (Mar 2025) to 67.00 Cr., marking an increase of 16.00 Cr..
- For Depreciation, as of Jun 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 12.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -228.00 Cr.. The value appears to be declining and may need further review. It has decreased from -157.00 Cr. (Mar 2025) to -228.00 Cr., marking a decrease of 71.00 Cr..
- For Tax %, as of Jun 2025, the value is -19.00%. The value appears to be improving (decreasing) as expected. It has decreased from -5.00% (Mar 2025) to -19.00%, marking a decrease of 14.00%.
- For Net Profit, as of Jun 2025, the value is -186.00 Cr.. The value appears to be declining and may need further review. It has decreased from -149.00 Cr. (Mar 2025) to -186.00 Cr., marking a decrease of 37.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -10.16. The value appears to be declining and may need further review. It has decreased from -8.11 (Mar 2025) to -10.16, marking a decrease of 2.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 2:21 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,605 | 1,414 | 1,386 | 1,627 | 1,839 | 1,167 | 1,121 | 476 | 618 | 773 | 1,614 | 1,561 | 1,502 |
| Expenses | 1,378 | 1,180 | 1,144 | 1,343 | 1,579 | 1,038 | 924 | 594 | 665 | 1,077 | 1,958 | 2,169 | 2,128 |
| Operating Profit | 226 | 234 | 242 | 284 | 260 | 128 | 198 | -119 | -47 | -303 | -343 | -608 | -626 |
| OPM % | 14% | 17% | 17% | 17% | 14% | 11% | 18% | -25% | -8% | -39% | -21% | -39% | -42% |
| Other Income | 30 | 34 | 54 | 59 | 59 | 34 | 28 | 39 | 20 | 25 | 21 | 76 | 48 |
| Interest | 131 | 144 | 147 | 155 | 169 | 74 | 108 | 161 | 121 | 113 | 130 | 195 | 220 |
| Depreciation | 10 | 14 | 10 | 9 | 9 | 9 | 73 | 63 | 47 | 65 | 54 | 37 | 37 |
| Profit before tax | 116 | 110 | 139 | 179 | 141 | 79 | 44 | -305 | -194 | -457 | -507 | -764 | -835 |
| Tax % | 32% | 46% | 45% | 41% | 39% | 38% | 319% | -23% | -17% | -23% | -20% | -10% | |
| Net Profit | 79 | 60 | 77 | 105 | 85 | 49 | -97 | -235 | -162 | -351 | -406 | -685 | -724 |
| EPS in Rs | 4.29 | 3.28 | 4.20 | 5.58 | 4.59 | 2.68 | -5.32 | -12.86 | -8.72 | -19.02 | -22.01 | -37.51 | -39.60 |
| Dividend Payout % | 12% | 15% | 17% | 13% | 15% | 26% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -24.05% | 28.33% | 36.36% | -19.05% | -42.35% | -297.96% | -142.27% | 31.06% | -116.67% | -15.67% | -68.72% |
| Change in YoY Net Profit Growth (%) | 0.00% | 52.38% | 8.03% | -55.41% | -23.31% | -255.61% | 155.69% | 173.33% | -147.73% | 101.00% | -53.05% |
Omaxe Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 7% |
| 3 Years: | 36% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 5% |
| 3 Years: | -5% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -39% |
| 3 Years: | -76% |
| Last Year: | -498% |
Last Updated: September 5, 2025, 11:55 am
Balance Sheet
Last Updated: October 10, 2025, 2:39 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 |
| Reserves | 1,746 | 1,794 | 1,848 | 1,936 | 2,014 | 1,558 | 1,456 | 1,222 | 1,062 | 715 | 298 | -388 |
| Borrowings | 1,299 | 1,346 | 1,328 | 1,503 | 1,802 | 1,856 | 1,672 | 1,530 | 1,128 | 1,107 | 796 | 796 |
| Other Liabilities | 3,225 | 3,585 | 4,353 | 4,704 | 4,129 | 7,163 | 7,239 | 8,108 | 9,545 | 11,555 | 12,546 | 14,300 |
| Total Liabilities | 6,453 | 6,908 | 7,712 | 8,326 | 8,128 | 10,760 | 10,549 | 11,042 | 11,918 | 13,560 | 13,822 | 14,891 |
| Fixed Assets | 131 | 118 | 600 | 604 | 604 | 599 | 747 | 671 | 627 | 582 | 565 | 606 |
| CWIP | 0 | 0 | -0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | 16 | 20 | 22 | 12 | 12 | 12 | 12 | 12 | 13 | 14 | 29 | 21 |
| Other Assets | 6,306 | 6,769 | 7,091 | 7,710 | 7,512 | 10,149 | 9,789 | 10,359 | 11,278 | 12,964 | 13,228 | 14,264 |
| Total Assets | 6,453 | 6,908 | 7,712 | 8,326 | 8,128 | 10,760 | 10,549 | 11,042 | 11,918 | 13,560 | 13,822 | 14,891 |
Below is a detailed analysis of the balance sheet data for Omaxe Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 183.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 183.00 Cr..
- For Reserves, as of Mar 2025, the value is -388.00 Cr.. The value appears to be declining and may need further review. It has decreased from 298.00 Cr. (Mar 2024) to -388.00 Cr., marking a decrease of 686.00 Cr..
- For Borrowings, as of Mar 2025, the value is 796.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2024) which recorded 796.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 14,300.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12,546.00 Cr. (Mar 2024) to 14,300.00 Cr., marking an increase of 1,754.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 14,891.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 13,822.00 Cr. (Mar 2024) to 14,891.00 Cr., marking an increase of 1,069.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 606.00 Cr.. The value appears strong and on an upward trend. It has increased from 565.00 Cr. (Mar 2024) to 606.00 Cr., marking an increase of 41.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 29.00 Cr. (Mar 2024) to 21.00 Cr., marking a decrease of 8.00 Cr..
- For Other Assets, as of Mar 2025, the value is 14,264.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,228.00 Cr. (Mar 2024) to 14,264.00 Cr., marking an increase of 1,036.00 Cr..
- For Total Assets, as of Mar 2025, the value is 14,891.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,822.00 Cr. (Mar 2024) to 14,891.00 Cr., marking an increase of 1,069.00 Cr..
However, the Borrowings (796.00 Cr.) are higher than the Reserves (-388.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 225.00 | 233.00 | 241.00 | 283.00 | 259.00 | 127.00 | 197.00 | -120.00 | -48.00 | -304.00 | -1,139.00 | -1,404.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 197 | 199 | 208 | 235 | 158 | 110 | 111 | 298 | 227 | 182 | 81 | 73 |
| Inventory Days | 16,214 | |||||||||||
| Days Payable | 1,755 | |||||||||||
| Cash Conversion Cycle | 197 | 199 | 208 | 235 | 158 | 110 | 111 | 298 | 227 | 182 | 14,539 | 73 |
| Working Capital Days | 470 | 601 | 570 | 547 | 461 | 532 | 508 | 911 | 424 | 156 | -62 | -333 |
| ROCE % | 8% | 8% | 9% | 10% | 8% | 4% | 5% | -5% | -3% | -16% | -23% | -61% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -37.51 | -22.01 | -19.02 | -8.72 | -12.86 |
| Diluted EPS (Rs.) | -37.51 | -22.01 | -19.02 | -8.72 | -12.86 |
| Cash EPS (Rs.) | -35.45 | -19.24 | -15.62 | -6.29 | -9.39 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -11.22 | 14.42 | 37.44 | 56.57 | 65.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -11.22 | 14.42 | 37.44 | 56.57 | 65.43 |
| Revenue From Operations / Share (Rs.) | 85.35 | 88.26 | 42.28 | 33.78 | 26.01 |
| PBDIT / Share (Rs.) | -29.07 | -17.64 | -15.23 | -1.46 | -4.36 |
| PBIT / Share (Rs.) | -31.08 | -20.61 | -18.81 | -4.01 | -7.83 |
| PBT / Share (Rs.) | -41.76 | -27.74 | -24.97 | -10.63 | -16.66 |
| Net Profit / Share (Rs.) | -37.46 | -22.20 | -19.20 | -8.84 | -12.86 |
| NP After MI And SOA / Share (Rs.) | -37.51 | -22.01 | -19.02 | -8.72 | -12.86 |
| PBDIT Margin (%) | -34.06 | -19.98 | -36.02 | -4.32 | -16.77 |
| PBIT Margin (%) | -36.41 | -23.35 | -44.47 | -11.86 | -30.10 |
| PBT Margin (%) | -48.92 | -31.42 | -59.06 | -31.46 | -64.04 |
| Net Profit Margin (%) | -43.89 | -25.15 | -45.39 | -26.16 | -49.44 |
| NP After MI And SOA Margin (%) | -43.94 | -24.93 | -44.98 | -25.82 | -49.43 |
| Return on Networth / Equity (%) | 0.00 | -157.76 | -51.69 | -15.64 | -19.93 |
| Return on Capital Employeed (%) | -61.52 | -23.15 | -16.47 | -3.32 | -5.47 |
| Return On Assets (%) | -4.61 | -2.91 | -2.56 | -1.33 | -2.12 |
| Long Term Debt / Equity (X) | -2.43 | 1.95 | 0.98 | 0.42 | 0.67 |
| Total Debt / Equity (X) | -3.62 | 2.86 | 1.37 | 0.90 | 0.80 |
| Asset Turnover Ratio (%) | 0.10 | 0.11 | 0.06 | 0.04 | 0.03 |
| Current Ratio (X) | 0.95 | 1.02 | 1.07 | 1.10 | 1.17 |
| Quick Ratio (X) | 0.16 | 0.15 | 0.16 | 0.15 | 0.15 |
| Inventory Turnover Ratio (X) | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -2.72 | -2.48 | -2.47 | -0.22 | -0.49 |
| Interest Coverage Ratio (Post Tax) (X) | -2.51 | -2.12 | -2.11 | -0.33 | -0.45 |
| Enterprise Value (Cr.) | 1437.16 | 1855.26 | 1453.09 | 2188.62 | 2001.51 |
| EV / Net Operating Revenue (X) | 0.92 | 1.15 | 1.88 | 3.54 | 4.21 |
| EV / EBITDA (X) | -2.70 | -5.75 | -5.22 | -81.94 | -25.08 |
| MarketCap / Net Operating Revenue (X) | 0.91 | 1.03 | 1.18 | 2.37 | 2.59 |
| Price / BV (X) | -6.96 | 6.50 | 1.36 | 1.44 | 1.04 |
| Price / Net Operating Revenue (X) | 0.91 | 1.03 | 1.18 | 2.37 | 2.59 |
| EarningsYield | -0.48 | -0.24 | -0.38 | -0.10 | -0.19 |
After reviewing the key financial ratios for Omaxe Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 5. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
- For Diluted EPS (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 5. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
- For Cash EPS (Rs.), as of Mar 25, the value is -35.45. This value is below the healthy minimum of 3. It has decreased from -19.24 (Mar 24) to -35.45, marking a decrease of 16.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -11.22. It has decreased from 14.42 (Mar 24) to -11.22, marking a decrease of 25.64.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -11.22. It has decreased from 14.42 (Mar 24) to -11.22, marking a decrease of 25.64.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 85.35. It has decreased from 88.26 (Mar 24) to 85.35, marking a decrease of 2.91.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -29.07. This value is below the healthy minimum of 2. It has decreased from -17.64 (Mar 24) to -29.07, marking a decrease of 11.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is -31.08. This value is below the healthy minimum of 0. It has decreased from -20.61 (Mar 24) to -31.08, marking a decrease of 10.47.
- For PBT / Share (Rs.), as of Mar 25, the value is -41.76. This value is below the healthy minimum of 0. It has decreased from -27.74 (Mar 24) to -41.76, marking a decrease of 14.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -37.46. This value is below the healthy minimum of 2. It has decreased from -22.20 (Mar 24) to -37.46, marking a decrease of 15.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 2. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
- For PBDIT Margin (%), as of Mar 25, the value is -34.06. This value is below the healthy minimum of 10. It has decreased from -19.98 (Mar 24) to -34.06, marking a decrease of 14.08.
- For PBIT Margin (%), as of Mar 25, the value is -36.41. This value is below the healthy minimum of 10. It has decreased from -23.35 (Mar 24) to -36.41, marking a decrease of 13.06.
- For PBT Margin (%), as of Mar 25, the value is -48.92. This value is below the healthy minimum of 10. It has decreased from -31.42 (Mar 24) to -48.92, marking a decrease of 17.50.
- For Net Profit Margin (%), as of Mar 25, the value is -43.89. This value is below the healthy minimum of 5. It has decreased from -25.15 (Mar 24) to -43.89, marking a decrease of 18.74.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -43.94. This value is below the healthy minimum of 8. It has decreased from -24.93 (Mar 24) to -43.94, marking a decrease of 19.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -157.76 (Mar 24) to 0.00, marking an increase of 157.76.
- For Return on Capital Employeed (%), as of Mar 25, the value is -61.52. This value is below the healthy minimum of 10. It has decreased from -23.15 (Mar 24) to -61.52, marking a decrease of 38.37.
- For Return On Assets (%), as of Mar 25, the value is -4.61. This value is below the healthy minimum of 5. It has decreased from -2.91 (Mar 24) to -4.61, marking a decrease of 1.70.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -2.43. This value is below the healthy minimum of 0.2. It has decreased from 1.95 (Mar 24) to -2.43, marking a decrease of 4.38.
- For Total Debt / Equity (X), as of Mar 25, the value is -3.62. This value is within the healthy range. It has decreased from 2.86 (Mar 24) to -3.62, marking a decrease of 6.48.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.10. It has decreased from 0.11 (Mar 24) to 0.10, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.95, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 1. It has increased from 0.15 (Mar 24) to 0.16, marking an increase of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.19, marking an increase of 0.19.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.72. This value is below the healthy minimum of 3. It has decreased from -2.48 (Mar 24) to -2.72, marking a decrease of 0.24.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.51. This value is below the healthy minimum of 3. It has decreased from -2.12 (Mar 24) to -2.51, marking a decrease of 0.39.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,437.16. It has decreased from 1,855.26 (Mar 24) to 1,437.16, marking a decrease of 418.10.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.15 (Mar 24) to 0.92, marking a decrease of 0.23.
- For EV / EBITDA (X), as of Mar 25, the value is -2.70. This value is below the healthy minimum of 5. It has increased from -5.75 (Mar 24) to -2.70, marking an increase of 3.05.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.91, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is -6.96. This value is below the healthy minimum of 1. It has decreased from 6.50 (Mar 24) to -6.96, marking a decrease of 13.46.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.91, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is -0.48. This value is below the healthy minimum of 5. It has decreased from -0.24 (Mar 24) to -0.48, marking a decrease of 0.24.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Omaxe Ltd:
- Net Profit Margin: -43.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -61.52% (Industry Average ROCE: 16.47%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 23.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.51
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.16
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 44.3)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -3.62
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -43.89%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Construction, Contracting & Engineering | Shop No. 19-B, First Floor, Gurgaon Haryana 122001 | secretarial_1@omaxe.com http://www.omaxe.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rohtas Goel | Chairman & Non-Exe.Director |
| Mr. Mohit Goel | Managing Director |
| Mr. Vinit Goyal | Whole Time Director |
| Ms. Nishal Jain | Non Exe. Women Independent Director |
| Mr. Shridhar Rao | Ind. Non-Executive Director |
| Mr. Aroon Kumar Aggarwal | Ind. Non-Executive Director |
| Ms. Binitha Manohar Dalal | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Omaxe Ltd?
Omaxe Ltd's intrinsic value (as of 14 October 2025) is 693.67 which is 744.91% higher the current market price of 82.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,502 Cr. market cap, FY2025-2026 high/low of 134/68.8, reserves of ₹-388 Cr, and liabilities of 14,891 Cr.
What is the Market Cap of Omaxe Ltd?
The Market Cap of Omaxe Ltd is 1,502 Cr..
What is the current Stock Price of Omaxe Ltd as on 14 October 2025?
The current stock price of Omaxe Ltd as on 14 October 2025 is 82.1.
What is the High / Low of Omaxe Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Omaxe Ltd stocks is 134/68.8.
What is the Stock P/E of Omaxe Ltd?
The Stock P/E of Omaxe Ltd is .
What is the Book Value of Omaxe Ltd?
The Book Value of Omaxe Ltd is 11.2.
What is the Dividend Yield of Omaxe Ltd?
The Dividend Yield of Omaxe Ltd is 0.00 %.
What is the ROCE of Omaxe Ltd?
The ROCE of Omaxe Ltd is 61.4 %.
What is the ROE of Omaxe Ltd?
The ROE of Omaxe Ltd is 506 %.
What is the Face Value of Omaxe Ltd?
The Face Value of Omaxe Ltd is 10.0.